CAPÍTULO V: IMPLEMENTACIÓN
5.2. Documentación del Sistema
5.2.1. Manual de instalación
[1] R¨ontgen WC. Ueber eine neue Art von Strahlen. Annalen der Physik, 300(1):12–17, 1898.
[2] NEMA . Performance measurements of gamma cameras. NEMA NU 2-2012. National Electrical Manufacturers Association, 2012.
[3] NEMA . Performance measurements of positron emision tomographs (PETs). NEMA NU 2-2012. National Electrical Manufacturers Association, 2012.
[4] Boellaard R. Standards for PET image acquisition and quantitative data analysis. J.Nucl.Med., 50 Suppl 1:11S–20S, 2009.
[5] Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, and Krause BJ. FDG PET and PET/CT: EANM procedure
guidelines for tumour PET imaging: version 1.0. Eur.J.Nucl.Med.Mol.Imaging, 37
(1):181–200, 2010.
[6] Phelps M. PET: Molecular Imaging and Its Biological Applications, pages 57–58. Springer Science & Business Media, 2004.
[7] Bray F, Lortet-Tieulent J, Ferlay J, Forman D, and Auvinen A. Prostate cancer
incidence and mortality trends in 37 European countries: an overview. Eur.J.Cancer,
46(17):3040–3052, 2010.
[8] Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der KT, Mason M, Matveev V, Wiegel T, Zattoni F, and Mottet N. EAU guidelines on prostate cancer.
part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
Eur.Urol., 65(1):124–137, 2014.
[9] Schwarzenbock S, Souvatzoglou M, and Krause BJ. Choline PET and PET/CT in
Primary Diagnosis and Staging of Prostate Cancer. Theranostics., 2(3):318–330,
2012.
[10] Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, and DeGrado TR.
Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emis- sion tomography of androgen dependent and androgen independent prostate cancer.
J.Urol., 168(1):273–280, 2002.
[11] Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, and Rachinsky I. 18F-
fluorocholine for prostate cancer imaging: a systematic review of the literature.
146 BIBLIOGRAPHY
[12] DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, Reiman R, Price DT, and Coleman RE. Synthesis and evaluation of (18)F-labeled choline analogs as
oncologic PET tracers. J.Nucl.Med., 42(12):1805–1814, 2001.
[13] Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S, Fuccio C, Rubello D, Castellucci P, Marzola MC, and Fanti S. Choline PET/CT for prostate cancer: main
clinical applications. Eur.J.Radiol., 80(2):e50–e56, 2011.
[14] Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, and Thalmann GN. The role of choline positron emission tomography/computed
tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur.Urol., 59(1):51–60, 2011.
[15] Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, Moller P, Glatting G, and Perner S. Imaging prostate cancer with 11C-choline PET/CT. J.Nucl.Med., 47(8):1249–1254, 2006.
[16] Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or
11C-choline. J.Nucl.Med., 52(1):81–89, 2011.
[17] Roivainen A, Forsback S, Gronroos T, Lehikoinen P, Kahkonen M, Sutinen E, and Minn H. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging
with positron emission tomography. Eur.J.Nucl.Med., 27(1):25–32, 2000.
[18] Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, and Minn H. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.
Eur.J.Nucl.Med.Mol.Imaging, 31(3):317–324, 2004.
[19] DeGrado TR, Reiman RE, Price DT, Wang S, and Coleman RE. Pharmacokinetics
and radiation dosimetry of 18F-fluorocholine. J.Nucl.Med., 43(1):92–96, 2002.
[20] Oprea-Lager DE, Vincent AD, van Moorselaar RJ, Gerritsen WR, van den Eertwegh AJ, Eriksson J, Boellaard R, and Hoekstra OS. Dual-phase PET-CT to differentiate
[18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. PLoS.One., 7(10):e48430, 2012.
[21] Tavola F, Janzen T, Giussani A, Facchinetti D, Veronese I, Uusijarvi-Lizana H, Matts- son S, Hoeschen C, and Cantone MC. Nonlinear compartmental model of 18F-choline. Nucl.Med.Biol., 39(2):261–268, 2012.
[22] Uusijarvi H, Nilsson LE, Bjartell A, and Mattsson S. Biokinetics of 18F-choline studied in four prostate cancer patients. Radiat.Prot.Dosimetry., 139(1-3):240–244,
2010.
[23] Windhorst AD, Linden TT, de Nooij A, Keus JF, Buijs FL, Schollema PE, van Rooij LF, and Herscheid JDM. A complete, multipurpose, low cost, fully automated and
GMP compliant radiosynthesis system. J.Label Compd Radiopharm, 44(Supplement
S1):S1052–S1054, 2001.
[24] Boellaard R, van LA, van Balen SC, Hoving BG, and Lammertsma AA. Charac-
teristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur.J.Nucl.Med., 28(1):81–89, 2001.
[25] Watabe H, Channing MA, Der MG, Adams HR, Jagoda E, Herscovitch P, Eckelman WC, and Carson RE. Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907. J.Cereb.Blood Flow Metab, 20(6):899–909, 2000.
[26] Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, and Frack- owiak RS. Comparison of methods for analysis of clinical [11C]raclopride studies. J.Cereb.Blood Flow Metab, 16(1):42–52, 1996.
147
B
[27] Yaqub M, Boellaard R, Kropholler MA, and Lammertsma AA. Optimization algo-
rithms and weighting factors for analysis of dynamic PET studies. Phys.Med.Biol.,
51(17):4217–4232, 2006.
[28] Glatting G, Kletting P, Reske SN, Hohl K, and Ring C. Choosing the optimal fit
function: comparison of the Akaike information criterion and the F-test. Med.Phys.,
34(11):4285–4292, 2007.
[29] Giovacchini G. Do we have to withdraw antiandrogenic therapy in prostate cancer
patients before PET/CT with [11C]choline? Eur.J.Nucl.Med.Mol.Imaging, 38(11):
1964–1966, 2011.
[30] Challapalli A, Sharma R, Hallett WA, Kozlowski K, Carroll L, Brickute D, Twyman F, Al-Nahhas A, and Aboagye EO. Biodistribution and radiation dosimetry of deuterium-substituted 18F-fluoromethyl-[1, 2-2H4]choline in healthy volunteers.
J.Nucl.Med., 55(2):256–263, 2014.
[31] Witney TH, Alam IS, Turton DR, Smith G, Carroll L, Brickute D, Twyman FJ, Nguyen QD, Tomasi G, Awais RO, and Aboagye EO. Evaluation of deuterated 18F-
and 11C-labeled choline analogs for cancer detection by positron emission tomography.
Clin.Cancer Res., 18(4):1063–1072, 2012.
[32] Jemal A, Siegel R, Xu J, and Ward E. Cancer statistics, 2010. CA Cancer J Clin, 60 (5):277–300, 2010.
[33] Jemal A, Siegel R, Ward E, Murray T, Xu J, and Thun MJ. Cancer statistics, 2007. CA Cancer J Clin, 57(1):43–66, 2007.
[34] Brambilla E, Travis WD, Colby TV, Corrin B, and Shimosato Y. The new World
Health Organization classification of lung tumours. Eur Respir.J, 18(6):1059–1068,
2001.
[35] DeVita VTHS and Rosenberg SA. Principles & practice of oncology. lippincott williams & wilkins, Philadelphia, 2008.
[36] Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest, 111(6):1710–1717, 1997.
[37] Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, and Genestreti G. Small cell
lung cancer. Annals of Oncology, 17(suppl 2):ii5–ii10, 2006.
[38] Goffin J, Lacchetti C, Ellis PM, Ung YC, and Evans WK. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a system- atic review. J Thorac.Oncol., 5(2):260–274, 2010.
[39] Grossi F, Kubota K, Cappuzzo F, de MF, Gridelli C, Aita M, and Douillard JY.
Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. Oncologist., 15(10):1102–1112, 2010.
[40] Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Find- lay B, Tu D, Johnston D, Bezjak A, Clark G, Santab´arbara P, and Seymour L. Er-
lotinib in previously treated non-small cell lung cancer. New England Journal of
Medicine, 353(2):123–132, 2005.
[41] Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szcz´ersna A, Juh´asz E, Esteban E, Molinier O, Brugger W, Melez´ınek I, Klingelschmitt G, Klughammer B, and Giaccone G. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a
multicentre, randomised, placebo-controlled phase 3 study. The Lancet Oncology, 11
148 BIBLIOGRAPHY
[42] Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn (W. D.) J, Morse D, Abra- ham S, Rahman A, Liang C, Lostritto R, Baird A, and Pazdur R. United States Food
and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets.
Clin Cancer Res, 10(4):1212–1218, 2004.
[43] Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, and Shepherd FA. Erlotinib in lung cancer
- molecular and clinical predictors of outcome. New England Journal of Medicine,
353(2):133–144, 2005.
[44] Paez JG, J¨anne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, and Meyerson M. EGFR mutations in lung cancer: correlation with clinical
response to gefitinib therapy. Science, 304(5676):1497–1500, 2004.
[45] Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, and Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England
Journal of Medicine, 350(21):2129–2139, 2004.
[46] Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, and Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell
lung cancer. New England Journal of Medicine, 355(24):2542–2550, 2006.
[47] Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De PT, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, and Janne PA. Crizotinib
versus chemotherapy in advanced ALK-positive lung cancer. N.Engl.J Med., 368(25):
2385–2394, 2013.
[48] Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O’Byrne KJ, Koong AC, and Giaccia AJ. An evaluation of tumor oxygenation and gene expression in patients with
early stage non-small cell lung cancers. Clinical Cancer Research, 12(5):1507–1514,
2006.
[49] Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, and Harris AL. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell
lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br.J Cancer, 89(5):877–885, 2003.
[50] Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC, and Harris AL. Relation of hypoxia inducible factor 1 alpha and 2 alpha in
operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br.J Cancer, 85(6):881–890, 2001.
[51] Swinson DEB, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, and OByrne KJ. Carbonic anhydrase IX expression, a novel surrogate
marker of tumor hypoxia, is associated with a poor prognosis in non-small cell lung cancer. Journal of Clinical Oncology, 21(3):473–482, 2003.
[52] Harrison LB, Chadha M, Hill RJ, Hu K, and Shasha D. Impact of tumor hypoxia and
anemia on radiation therapy outcomes. The Oncologist, 7(6):492–508, 2002.
[53] Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, and Yu J. Hypoxia-induced resistance
to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of
149
B
[54] Vaupel P and Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev., 26(2):225–239, 2007.
[55] Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med, 7(9):987–989, 2001.
[56] Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat.Rev.Cancer, 2(1): 38–47, 2002.
[57] Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG, Oost- erwijk E, and Kelley MJ. Expression of HIF-1a, CA IX, VEGF, and MMP-9 in
surgically resected non-small cell lung cancer. Lung Cancer, 49(3):325–335, 2005.
[58] Younes M, Brown RW, Stephenson M, Gondo M, and Cagle PT. Overexpression
of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer, 80(6):1046–1051, 1997.
[59] Le QT and Courter D. Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev., 27(3):351–362, 2008.
[60] Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, and Vaupel P. Association
between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research, 56(19):4509–4515, 1996.
[61] Carlin S and Humm JL. PET of hypoxia: current and future perspectives.
J.Nucl.Med., 53(8):1171–1174, 2012.
[62] Brown JM and Wilson WR. Exploiting tumour hypoxia in cancer treatment.
Nat.Rev.Cancer, 4(6):437–447, 2004.
[63] Wilson WR and Hay MP. Targeting hypoxia in cancer therapy. Nat.Rev.Cancer, 11 (6):393–410, 2011.
[64] Gunn RN, Gunn SR, and Cunningham VJ. Positron emission tomography compart-
mental models. J.Cereb.Blood Flow Metab, 21(6):635–652, 2001.
[65] Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, and Steinert HC. Staging of non-small-cell lung cancer with integrated positron-
emission tomography and computed tomography. N.Engl.J.Med., 348(25):2500–2507,
2003.
[66] van TH, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, van Velthoven PC, Comans EF, Diepenhorst FW, Verboom P, van Mourik JC, Postmus PE, Boers M, and Teule GJ. Effectiveness of positron emission tomography in the
preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet, 359(9315):1388–1393, 2002.
[67] Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, Fidler V, Pruim J, and Groen HJ. Preoperative staging of non-small-cell lung
cancer with positron-emission tomography. N.Engl.J.Med., 343(4):254–261, 2000.
[68] Dierckx RA and Van de WC. FDG uptake, a surrogate of tumour hypoxia?
Eur.J.Nucl.Med.Mol.Imaging, 35(8):1544–1549, 2008.
[69] Gray LH, Conger AD, Ebert M, Hornsey S, and Scott OC. The concentration of
oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy.
Br.J.Radiol., 26(312):638–648, 1953.
[70] Chapman JD, Dugle DL, Reuvers AP, Meeker BE, and Borsa J. Letter: Studies on
the radiosensitizing effect of oxygen in Chinese hamster cells. Int.J.Radiat.Biol.Relat
150 BIBLIOGRAPHY
[71] Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev., 13(2):139–168, 1994.
[72] Tredan O, Galmarini CM, Patel K, and Tannock IF. Drug resistance and the solid
tumor microenvironment. J.Natl.Cancer Inst., 99(19):1441–1454, 2007.
[73] Semenza GL. Targeting HIF-1 for cancer therapy. Nat.Rev.Cancer, 3(10):721–732, 2003.
[74] Hu Y, Liu J, and Huang H. Recent agents targeting HIF-1alpha for cancer therapy. J.Cell Biochem., 114(3):498–509, 2013.
[75] von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, and Treat J. Tirapazamine plus cisplatin versus
cisplatin in advanced non-small-cell lung cancer: A report of the international CATA- PULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small cell lung tumors. J.Clin.Oncol., 18(6):1351–1359, 2000.
[76] Henk JM, Kunkler PB, and Smith CW. Radiotherapy and hyperbaric oxygen in head
and neck cancer. Final report of first controlled clinical trial. Lancet, 2(8029):101–103,
1977.
[77] Kaanders JH, Bussink J, and van der Kogel AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol., 3(12):728–737, 2002.
[78] Fyles AW, Milosevic M, Pintilie M, Syed A, and Hill RP. Anemia, hypoxia and transfusion in patients with cervix cancer: a review. Radiother.Oncol., 57(1):13–19,
2000.
[79] Jordan BF and Sonveaux P. Targeting tumor perfusion and oxygenation to improve
the outcome of anticancer therapy. Front Pharmacol., 3:94, 2012.
[80] Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindelov B, and Jorgensen K. A randomized double-blind phase III study of nimorazole as
a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and phar- ynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother.Oncol., 46(2):135–146, 1998.
[81] Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol., 6(2):112–117, 2005.
[82] Brown JM and Workman P. Partition coefficient as a guide to the development of
radiosensitizers which are less toxic than misonidazole. Radiat.Res., 82(1):171–190,
1980.
[83] Chapman JD. The detection and measurement of hypoxic cells in solid tumors. Can- cer, 54(11):2441–2449, 1984.
[84] Krohn KA, Link JM, and Mason RP. Molecular imaging of hypoxia. J.Nucl.Med., 49 Suppl 2:129S–148S, 2008.
[85] Bruehlmeier M, Roelcke U, Schubiger PA, and Ametamey SM. Assessment of hypoxia
and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J.Nucl.Med., 45(11):1851–1859, 2004.
[86] Wang W, Lee NY, Georgi JC, Narayanan M, Guillem J, Schoder H, and Humm JL.
Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer. J.Nucl.Med., 51(1):37–45, 2010.
151
B
[87] Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, Dannenberg C, Tannapfel A, Kluge R, and Sabri O. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl.Med.Biol., 30(3):
317–326, 2003.
[88] Trinkaus ME, Blum R, Rischin D, Callahan J, Bressel M, Segard T, Roselt P, Eu P, Binns D, MacManus MP, Ball D, and Hicks RJ. Imaging of hypoxia with 18F-FAZA
PET in patients with locally advanced non-small cell lung cancer treated with defini- tive chemoradiotherapy. J.Med.Imaging Radiat.Oncol., 57(4):475–481, 2013.
[89] Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, and Podoloff DA. De-
velopment of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology, 194(3):795–800, 1995.
[90] Dubois LJ, Lieuwes NG, Janssen MH, Peeters WJ, Windhorst AD, Walsh JC, Kolb HC, Ollers MC, Bussink J, van Dongen GA, van der KA, and Lambin P. Preclin-
ical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc.Natl.Acad.Sci.U.S.A, 108(35):14620–14625, 2011.
[91] Petering HG, Buskirk HH, and Underwood GE. The anti-tumor activity of 2-keto-3-
ethoxybutyraldehyde bis(thiosemicarbazone) and related compounds. Cancer Res., 24:
367–372, 1964.
[92] Paterson BM and Donnelly PS. Copper complexes of bis(thiosemicarbazones):
from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals.
Chem.Soc.Rev., 40(5):3005–3018, 2011.
[93] Lewis J, Laforest R, Buettner T, Song S, Fujibayashi Y, Connett J, and Welch M. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy. Proc.Natl.Acad.Sci.U.S.A, 98(3):1206–1211, 2001.
[94] Obata A, Kasamatsu S, Lewis JS, Furukawa T, Takamatsu S, Toyohara J, Asai T, Welch MJ, Adams SG, Saji H, Yonekura Y, and Fujibayashi Y. Basic characterization
of 64Cu-ATSM as a radiotherapy agent. Nucl.Med.Biol., 32(1):21–28, 2005.
[95] McCall KC, Humm JL, Bartlett R, Reese M, and Carlin S. Copper-64-diacetyl- bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia. Int.J.Radiat.Oncol.Biol.Phys., 84
(3):e393–e399, 2012.
[96] Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, and Okazawa H. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J.Nucl.Med., 50(12):1948–1953, 2009.
[97] Dearling JL and Packard AB. Some thoughts on the mechanism of cellular trapping
of Cu(II)-ATSM. Nucl.Med.Biol., 37(3):237–243, 2010.
[98] Vavere AL and Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of
hypoxia. Dalton Trans.
[99] Basken NE, Mathias CJ, Lipka AE, and Green MA. Species dependence of [64Cu]Cu-Bis(thiosemicarbazone) radiopharmaceutical binding to serum albumins.
Nucl.Med.Biol., 35(3):281–286, 2008.
[100] Burgman P, O’Donoghue JA, Lewis JS, Welch MJ, Humm JL, and Ling CC. Cell
line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl.Med.Biol., 32(6):623–630, 2005.
152 BIBLIOGRAPHY
[101] O’Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, and Humm JL.
Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-